STE
Healthcare · Medical Devices
Performance
STE (STE) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
STE (STE) operates in the Medical Devices space within the Healthcare sector. With a market cap of $20.2B, it qualifies as a mid-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.
- Forward P/E (17.1×) is lower than trailing P/E (26.2×) — analysts expect earnings to improve
- Revenue growth of 7% YoY shows solid business momentum
- Earnings grew 52% YoY — bottom-line is expanding fast
- Healthy profit margin of 13.2%
- Current ratio of 2.1× — ample short-term liquidity
- Price is near its 52-week low — potential entry point with asymmetric upside
- P/E of 26.2× is above average — valuation requires continued strong growth to justify
- High debt-to-equity of 29.00× increases financial risk, especially with elevated interest rates
Verdict
Strong Buy
Multiple fundamental strengths with few red flags. Long-term buyers may find this compelling.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
Current DY
1.22%
5Y Avg Annual
$1.7980
Last Payment
$0.6300
Ex-Date
06/08/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest06/08/2026 | 06/26/2026 | $0.6300 | 1.22% |
02/17/2026 | 03/07/2026 | $0.6300 | 1.22% |
09/04/2025 | 09/22/2025 | $0.6300 | 1.22% |
06/10/2025 | 06/28/2025 | $0.5700 | 1.10% |
02/20/2025 | 03/10/2025 | $0.5700 | 1.10% |
11/19/2024 | 12/07/2024 | $0.5700 | 1.10% |
09/05/2024 | 09/23/2024 | $0.5700 | 1.10% |
06/12/2024 | 06/30/2024 | $0.5200 | 1.00% |
Magic Number
Shares needed to self-fund your next purchase
$207.39
Price
$0.6300
Last div. (semesterly)
330
shares
Own 330 STE shares ($68,438.70) and each semesterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$68,438.70
New shares / year
+2 shares
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Aug 5, 2026
50
days
EPS (TTM)
$7.93
P/E (TTM)
26.2
Fwd P/E
17.1
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $207.39
Graham Number
√(22.5 × EPS × Book Value)
$114.48
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$31.30
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
9/10
90% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
11.4%Return on equity — measures how efficiently capital is used
Positive profit margin
13.2%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+7.3%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+52.2%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
29.00×Low financial leverage reduces risk of distress
Current ratio above 1
2.09×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$157M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
1.22%Stock must distribute income to shareholders
Related Assets
Healthcare
About STE
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.